| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Vesicle-fusing ATPase; N-ethylmaleimide-sensitive fusion protein; NEM-sensitive fusion protein; Vesicular-fusion protein NSF; NSF |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human ADAMTS13 recombinant protein (Position: D298-T1427). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-ADAMTS13 Antibody Picoband® is an antibody for ADAMTS13 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: ADAMTS13 (N-ethylmaleimide sensitive factor, vesicle fusing ATPase); UniProt: Q76LX8
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 154 kDa
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-ADAMTS13 Antibody Picoband® catalog # A00586-1.
Biological background
Biological context: Required for vesicle-mediated transport. Catalyzes the fusion of transport vesicles within the Golgi cisternae. Is also required for transport from the endoplasmic reticulum to the Golgi stack. Seems to function as a fusion protein required for the delivery of cargo proteins to all compartments of the Golgi stack independent of vesicle origin. Interaction with AMPAR subunit GRIA2 leads to influence GRIA2 membrane cycling (By similarity).
Expression and localization notes: cellular localization: Cytoplasm..
Common research applications
- Western blotting (WB): Compare ADAMTS13 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of ADAMTS13 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify ADAMTS13-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: ADAMTS13 (a disintegrin and metalloproteinase with athrombospondin type 1 motif, member 13), also known as VWFCP, is a zinc-containing metalloprotease enzyme that cleaves von Willebrand factor (vWf), a large protein involved in blood clotting. It is secreted in blood and degrades large vWf multimers, decreasing their activity. This gene encodes a member of a family of proteins containing several distinct regions, including a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. This gene is mapped to 9q34.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Cytoplasm.
- Research category: ATPases,Cancer,Metabolism,Neuroscience,Neurotransmission,Plasma Membrane,Protein Trafficking,Secretory Vesicles,Signal Transduction,Vesicle Transport
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.